1503TiP A phase II study of cemiplimab plus BNT116 versus cemiplimab alone in first-line treatment of patients with advanced non-small cell lung cancer with PD-L1 expression ≥50%Mark M. Awad, P. Rietschel, S. Li et al.|Annals of Oncology|2023Cited by 4